SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

Published: Saturday, May 31, 2025 at 12:55 pm

Faruqi & Faruqi Investigates Zenas BioPharma (ZBIO) Claims: Investors Urged to Act

New York, NY – May 31, 2025 – Leading securities law firm Faruqi & Faruqi, LLP is investigating potential claims against Zenas BioPharma, Inc. (NASDAQ: ZBIO) on behalf of investors. The firm is specifically looking into whether Zenas and its executives violated federal securities laws.

The investigation centers around allegations that Zenas BioPharma made false and misleading statements, including overstating the company's ability to fund its operations using existing cash and IPO proceeds. This, according to the complaint, led to investor damages when the truth came to light.

Investors who purchased or acquired Zenas stock in the initial public offering (IPO) held around September 13, 2024, are encouraged to contact Faruqi & Faruqi partner Josh Wilson directly to discuss their legal options. The deadline to seek the role of lead plaintiff in the federal securities class action is June 16, 2025. Investors can contact Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) or visit www.faruqilaw.com/ZBIO for more information.

The role of lead plaintiff is open to the investor with the largest financial interest in the relief sought by the class. However, all investors, regardless of whether they choose to become lead plaintiff, may share in any potential recovery. Faruqi & Faruqi also encourages anyone with information regarding Zenas' conduct, including whistleblowers, former employees, and shareholders, to contact the firm.

BNN's Perspective: While these types of investigations are common in the financial world, it's important for investors to carefully consider their options and consult with legal counsel. The allegations against Zenas, if proven true, raise serious concerns about transparency and financial reporting. Investors should weigh the potential benefits of participating in the class action against the risks and time commitment involved.

Keywords: Zenas BioPharma, ZBIO, Faruqi & Faruqi, securities lawsuit, investor lawsuit, class action, IPO, Josh Wilson, NASDAQ, financial fraud, misleading statements, shareholder rights, lead plaintiff, June 16 deadline, investor losses, federal securities laws, whistleblower, stock market, legal action, investment, litigation.

Full Story